AstraZeneca's latest lung cancer trial fails its primary endpoint
(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Read more